Scientific Publications

ST1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model
(Nasr RR et al, Int. J  Cancer, December 2014)  
(epub ahead of print) 

A multi-state model approach for prediction in chronic myeloid leukemia
(Lanseker M et al. Ann Hematol, Dec 2014) 
(epub ahead of print)

 DPPIV (CD26) as a novel stem cell marker in PH+ CML
(Valent P. Eur J Clin Invest, November 2014) 
(epub ahead of print)

Real-World cost-effectiveness in chronic myeloid leukemia: The price of success during four decades of development from non-targeted treatment to imatinib 
(Ohm L et al. Leuk Lymphoma, August 2014) 
(epub ahead of print)

Chronic myelogenous leukemia, version 1.2015
(O'Brian S et al. J Natl Can Netw, November 2014)

A phase 2 study of MK-0457 in patients with BCR-ABL T314l mutant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia
(Seymour JF et al. Blood Cancer J, August 2014)

Upregulated MSI2 is associated with more aggressive leukemia
(Kaeda J et al. Leuk Lymphoma, November 2014) 
(epub ahead of print)

Extending the reach of nilotinib in chronic myeloid leukemia 
(Mauro MJ. Haematologica, July 2014)

Predicting early blast transformation in chronic phase chronic myeloid leukemia: Is immunophenotyping the missing link?
(El Rassi F et al. Cancer, November 2014) 
(epub ahead of print)

Prognosis for patients with CML and >10% BCR-ABL1 after 3 month of imatinib depends on the rate of BCR-ABL1
(Branford et al. Blood, July 2014)

BCR-ABL 1 promotes leukemia by converting p27 into a cytoplastic oncoprotein 
(Agarwal A. Blood, October 2014) 
(epub ahead of print)

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
(Hughes et al. Haematologica, July 2014) 

The Antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors
(Pellicano F et al. Stem Cells, Sept. 2014)

Potential mechanisms of disease progression and management of advance phase CML
(Jabbour et al. Leuk Lymphoma, July 2014)

Molecular defined clonal evolution in patients with CML independent of the BCR-ABL status 
(Schmidt M et al. Leukemia, September 2014) 
(epub ahead of print)

How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for CML
(Ross et al. Br J Hematol, July 2014)

Structure, function and resistance in CML
(Radich J. Cancer Cell, September 2014)

Deep molecular response achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib
(Hughes et al. Blood, June 2014)

A therapeutically targetable mechanism of BCR-ABL independent imatinib resistance in CML
(Ma et al. Sci Transl. Med, September 2014)

Definition and treatment of resistance to tyrosine kinase inhibitors in CML
(Baccarani et al. Expert Rev Hematol, June 2014)

BCR-ABL Compound Mutations communing key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positivie leukemia
(Zabriskie MS et al. Cancer Cell, August 2014)

Long-term response to imatinib is not affected by the initial dose in patients with Ph+ CML in chronic phase: final update from the tyrosine kinase inhibitor optimization and selectivity (TOPS) study
(Baccarani et al. Int J Hematol, May 2014)

JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cell in vitro and in vivo
(Gallipoli P et al. Blood, August 2014)

Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: Treatment-free remission as a new goal in chronic myeloid leukemia
(Breccia et al. Cancer Lett, May 2014)

Combined STAT3 and BCR-ABL inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia 
(Eiring AM et al. Leukemia, August 2014) 
(epub ahead of print)

Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges 
(Noens et al. Haematologica, March 2014)

Change or die: Targeting adaptive signaling to kinase inhibition in cancer cells
(Rebecca VW et al. Biochem Pharmacol, August 2014)

Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis
(Signorovitch et al. Cancer Treat Rev, March 2014)

A pharmacodynamic model of BCR-ABL signaling in chronic myeloid leukaemia
(Jackson RC et al. Cancer Chemoter Pharmacol, August 2014)

Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden 

(Baccarani et al. Haematologica, Feb. 2014)

A certified plasmid reference material for the standardization of BCR-ABL1 mRNA quantification by real time quantitative PCR
(White et al. Leukemia, July 2014) 
(epub ahead of print)

Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia 

(Anderson et al. J Oncol Pharm Treat, Feb. 2014) 
(epub ahead of print)

Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with CML in chronic phase
(Lauseker M. J Cancer Res Clin Oncol, June 2014)

Predicting Outcomes in Patients With Chronic Myeloid Leukemia at Any Time During Tyrosine Kinase Inhibitor Therapy 

(Quintás-Cardema et al. Clin Lymphoma Myeloma Leu, Jan 2014)

Treatment Recommendations for Chronic Myeloid Leukemia 

(Baccarani et al. Mediterr J Hematol Infect Dis, Jan 2014)

Deep molecular response in chronic myeloid leukemia: the new goal of therapy? 

(Mahon et al. Clin Cancer Res, Jan 2014)

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 
(Baccarani et al. Blood, Aug 2013)